Menu Search
Equities

Exelixis Inc

EXEL:NSQ

Exelixis Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)35.40
  • Today's Change0.565 / 1.62%
  • Shares traded155.98k
  • 1 Year change+64.63%
  • Beta0.5073
Data delayed at least 15 minutes, as of Nov 22 2024 15:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Exelixis Inc grew revenues 13.60% from 1.61bn to 1.83bn while net income improved 13.98% from 182.28m to 207.77m.
Gross margin96.25%
Net profit margin22.43%
Operating margin25.13%
Return on assets15.73%
Return on equity20.20%
Return on investment18.08%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Exelixis Inc fell by 239.68m. However, the company earned 333.32m from its operations for a Cash Flow Margin of 18.21%. In addition the company used 26.96m on investing activities and also paid 546.05m in financing cash flows.
Cash flow per share1.64
Price/Cash flow per share20.11
Book value per share7.96
Tangible book value per share7.74
More ▼

Balance sheet in USDView more

Exelixis Inc uses little or no debt in its capital structure.
Current ratio3.93
Quick ratio3.88
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 15.08%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)-21.77
EPS (TTM) vs
TTM 1 year ago		459.21
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.